Magnus Financial Group LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 4,381 shares of the biotechnology company’s stock, valued at approximately $231,000.
A number of other hedge funds have also recently added to or reduced their stakes in the business. California State Teachers Retirement System lifted its stake in shares of Repligen by 2.3% in the fourth quarter. California State Teachers Retirement System now owns 61,228 shares of the biotechnology company’s stock valued at $3,229,000 after buying an additional 1,405 shares during the period. Ibex Investors LLC bought a new stake in shares of Repligen in the fourth quarter valued at about $224,000. United Services Automobile Association lifted its stake in shares of Repligen by 2.3% in the fourth quarter. United Services Automobile Association now owns 119,400 shares of the biotechnology company’s stock valued at $6,297,000 after buying an additional 2,643 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Repligen in the fourth quarter valued at about $307,000. Finally, Great West Life Assurance Co. Can lifted its stake in shares of Repligen by 13.5% in the fourth quarter. Great West Life Assurance Co. Can now owns 52,349 shares of the biotechnology company’s stock valued at $2,549,000 after buying an additional 6,208 shares during the period. Institutional investors own 90.66% of the company’s stock.
Several equities research analysts recently weighed in on RGEN shares. BidaskClub cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. CL King upgraded shares of Repligen from a “neutral” rating to a “buy” rating in a research note on Monday, December 17th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a research note on Wednesday, November 28th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Repligen has a consensus rating of “Buy” and a consensus target price of $59.20.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.21. Repligen had a net margin of 8.56% and a return on equity of 5.51%. The firm had revenue of $51.90 million during the quarter, compared to analyst estimates of $50.27 million. During the same quarter in the prior year, the business posted $0.20 earnings per share. The company’s quarterly revenue was up 24.8% compared to the same quarter last year. Analysts expect that Repligen Co. will post 0.83 EPS for the current fiscal year.
In related news, CFO Jon Snodgres sold 1,875 shares of the stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $58.88, for a total value of $110,400.00. Following the completion of the transaction, the chief financial officer now owns 26,821 shares of the company’s stock, valued at $1,579,220.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 13,000 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $58.50, for a total transaction of $760,500.00. Following the completion of the transaction, the chief executive officer now directly owns 229,657 shares of the company’s stock, valued at approximately $13,434,934.50. The disclosure for this sale can be found here. Insiders sold 27,731 shares of company stock valued at $1,625,768 in the last three months. Company insiders own 1.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/4223332/magnus-financial-group-llc-takes-231000-position-in-repligen-co-rgen.html.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Story: How does new data get added to a blockchain?
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.